New Targeted Therapy for Advanced Melanoma Lengthens Patients’ Lives

Another update from ASCO - Zelboraf is what I'm taking right now.  I haven't heard much about Trametnib until now but will ask my doctor about when I see him on the 15th.

I guess again the good news in the world of Melanoma (always trying to be the optimist) is that up until last year there had been no new advances in the treatment of Melanoma.  The FDA approved 3 drugs last year!  And while we will all complain about the costs of the drugs and how much profit the drug companies are making - when it comes down to it - if they are making a profit they are interested in developing more...  it's really a double edged sword...  

So stay tuned!  I know these articles have more info than some want - but again it's nice to know that there is still a lot of discussion and interest in developing new drugs to treat Melanoma.

New Targeted Therapy for Advanced Melanoma Lengthens Patients’ Lives

A recent study showed that the drug trametinib slowed tumor growth and lengthened the lives of patients who have advanced melanoma with a BRAF gene mutation (change). Trametinib is a type of treatment called targeted therapy. Targeted therapy targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Currently, there is one targeted therapy approved to treat melanoma that targets the BRAFgene, called vemurafenib (Zelboraf). However, vemurafenib eventually stops controlling melanoma growth for most patients, highlighting the need for other treatment options. Trametinib targets the MEK protein, which affects melanoma growth similarly to a mutated BRAF gene, which is why researchers are studying this treatment for melanoma.
The patients who participated in this study had advanced melanoma with a BRAF mutation and had received either one treatment or no treatment before the study began. During the study, they received trametinib or standard chemotherapy with either dacarbazine (DTIC-Dome) or paclitaxel (Taxol). Trametinib slowed or stopped melanoma growth for 22% of patients receiving the drug, compared with 8% of those who received chemotherapy.
Trametinib also lengthened the amount of time it took for the melanoma to worsen by a little more than three months when compared with chemotherapy. After six months, 81% of patients taking trametinib were living with the disease, compared with 67% of those who received chemotherapy. Because trametinib worked so well to control melanoma growth in this study, almost half of the patients who had their disease worsen while receiving chemotherapy were switched to trametinib.  
The side effects of trametinib were generally manageable for patients in this study and included rashes, eye problems, high blood pressure, and reduced heart function.
What this means for patients
"This is the first in a new type of targeted drugs that could benefit patients with melanoma who have BRAF gene mutations. The findings show that blocking the MEK protein is an effective treatment for many people with the disease," said lead author Caroline Robert, MD, PhD, Head of Dermatology at the Institute Gustave Roussy in Paris, France. "Trametinib is likely to become another initial treatment option for patients with advanced melanoma." Because research on trametinib is ongoing, it is currently only available in clinical trials. It’s important to talk with your doctor about all treatment options for melanoma, including clinical trials.

You Might Also Like